Omega (OMGA) - Forward P/S Multiple
The future P/S multiple dynamics for Omega Therapeutics (OMGA) are subject to liquidity shortage risks and potential delays in mRNA platform trials. Meanwhile, business development remains independent of macroeconomics and GDP, while the operating model relies on external production outsourcing. The current value of 0.90 represents a metric level that allows an investor to promptly identify overvalued expectations or fundamental sales growth.
Metric breakdowns and analytics for Omega Therapeutics Corp (OMGA)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Omega Therapeutics|OMGA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Omega Therapeutics|OMGA - Company Cumulative Indebtedness|Debts to Book Capitalization Omega Therapeutics Corp|OMGA - Long-Term Debt Volume|Company Short-Term Debts Omega Therapeutics|Quick Liquidity omegatherapeutics.com
- business earnings and investment ratios data:
OMGA - Net Financial Result|Expected Profit Omega Therapeutics|OMGA - Market Cap to Earnings|Future Price to Earnings Omega|OMGA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Omega Therapeutics Corp|OMGA - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Omega Therapeutics|OMGA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth omegatherapeutics.com|OMGA - Earnings per share growth this year|Net earnings per share growth forecast for next year Omega Therapeutics
- sales volume and revenue information:
General company analysis:Omega Therapeutics, Inc. OMGA
Investors use this indicator to determine the degree of overpayment for future cash flows in the absence of current earnings. The expected P/S ratio compares the market value of Omega Therapeutics (OMGA) with revenue forecasts, allowing for an assessment of capitalization potential through the lens of the epigenetic programming platform's development and the prospects for implementing oncology therapy drugs.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN - Forward P/S Multiple|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CRSP (crisprtx.com)|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|Forward P/S Multiple Sarepta Corp (SRPT)|Twist Bioscience - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TXG (10xgenomics.com)|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Wave Pharma|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|sionnatx.com (SION) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Prime Medicine (PRME)|TSHA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX - Forward Price-to-Revenue Multiple|REGENXBIO Inc. - Forward P/S Multiple|Projected Price to Revenue solidbio.com (SLDB)|OCGN: Forward P/S Multiple|Pacific Biosciences of California, Inc. (PACB) - Forward P/S Multiple|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Corp)|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|Forward P/S Multiple Korro Bio Inc. KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Silence Therapeutics Corp|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Codexis|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Nautilus Biotechnology Inc NAUT|Forward P/S Multiple MGX|Precision BioSciences Inc. (DTIL) - Projected Price to Revenue|Forward P/S Multiple GBIO (Generation Bio)|Forward P/S Multiple boundlessbio.com BOLD|XCUR: Forward Price-to-Revenue Multiple|Forward Price to Sales IMNN (Imunon, Inc.)|PHIO (phiopharma.com) - Forward Price-to-Revenue Multiple|MBIO: Price to Expected Revenue Ratio|RNAZ (TransCode Therapeutics Inc.) - Forward P/S Multiple|BNGO: Forward Price to Sales|Forward P/S Multiple APDN|BLUE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ImmunoPrecise Antibodies Ltd. IPA|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS - Forward P/S Multiple|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX (Unity Bio) - Forward P/S Multiple
